RESULTS OF A RANDOMIZED PROSPECTIVE STUDY OF INDUCTION THERAPY WITH DACLIZUMAB VERSUS THYMOGLOBULIN AMONG CROSSMATCH POSITIVE RENAL TRANSPLANT RECIPIENTS: 521